Detection of immune checkpoint markers in peripheral blood mononuclear cell lysates with AlphaLISA

September 19, 2018

Peripheral blood mononuclear cells (PBMCs) are a heterogeneous the population of blood cells having round nuclei. They consist of monocytes, macrophages, dendritic cells and lymphocytes (T cells, B cells, and NK cells). In order to induce and upregulate the expression of specific immune checkpoint markers in the PBMC populations, we used Dynabeads®, polystyrene-coated microspheres with antibodies against human CD3 and CD28 proteins covalently coupled to the surface.

Spotlight

BioHouston, Inc.

BioHouston, Inc. is a non-profit, tax-exempt [501(c)(3)] corporation founded by Houston-region academic/research institutions. We are leading a broad effort to establish the Houston region as a vigorous global competitor in life science and biotechnology commercialization.

OTHER WHITEPAPERS
news image

Characterization and identification of glucuronide metabolites

whitePaper | April 21, 2023

This technical note demonstrates the comprehensive characterization and confident identification of glucuronide metabolites from hepatocyte incubations of midazolam. An orthogonal fragmentation mechanism was applied to generate diagnostic fragmentions for confident identification of glucuronide metabolites

Read More
news image

Enabling the Future of Cell & Gene Therapies through Non Proprietary Patient-Owned Data Collection

whitePaper | March 16, 2021

Cell and gene therapies have emerged as a new treatment paradigm, and with them has come the potential to alter the course of many rare diseases. In many cases, there is an opportunity to correct the underlying dysfunction with a one-time administration of a therapy and provide either a functional cure or a substantial improvement in health outcomes. In other cases, long term symptom relief will be the primary therapeutic objective. Some of these indications may require more than one dose to achieve continued symptom relief and scientists and companies are working on technologies that will enable the use of a repeat dose.

Read More
news image

Document quality control emerges as a discipline in its own right

whitePaper | November 19, 2022

Compiling a quality regulatory submission is a basic requirement for biopharmaceutical companies. Poor quality documents could lead to rejection of a regulatory application,

Read More
news image

A Cornerstone in the Supply Chain of Cell-based Therapies

whitePaper | February 15, 2023

The diverse therapeutic attributes of mesenchymal stromal cells (MSCs) lend to their rapid development as cellular therapeutics. These unique attributes include potent immu nomodulatory properties [1,2], the potential to differentiate into multiple cell lineages.

Read More
news image

Improve Your Gene-Editing Success With CRISPR-SNIPER Technology

whitePaper | February 15, 2023

The discovery of both CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) and associated proteins, the Cas nucleases, has revolutionized the field of gene-editing.

Read More
news image

Pioneering Cell and Gene Therapy Solutions From Discovery to the Clinic

whitePaper | April 14, 2020

Your vision is to create revolutionary cell and gene therapies to treat life threatening diseases. Bio-Techne and its family of brands is on this journey with you. As a full-solution ancillary reagent and services provider, we will stand by you, providing flexible and pioneering tools to simplify your workflow. From CAR T cells to pluripotent stem cells, let us help you get your therapy to the patients that need it

Read More

Spotlight

BioHouston, Inc.

BioHouston, Inc. is a non-profit, tax-exempt [501(c)(3)] corporation founded by Houston-region academic/research institutions. We are leading a broad effort to establish the Houston region as a vigorous global competitor in life science and biotechnology commercialization.

Events